Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960266 | 0.98 | ALDH1A1 (0.37) | ESR1ESR2CXCR1TSHRSIGMAR1 | |
| SCHEMBL2180083 | 0.83 | TSHR (0.53) | TSHRHRH1KDM4ESMN1; SMN2LTA4H | |
| SCHEMBL11088044 | 0.83 | MEN1 (0.41) | ESR1ESR2TSHRSIGMAR1KDM4E | |
| SCHEMBL3583393 | 0.82 | HRH3 (0.54) | HRH3HRH1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL956747 | 0.81 | LTA4H (0.51) | TSHRCYP2D6LTA4H | |
| SCHEMBL8623642 | 0.80 | ALDH1A1 (0.55) | HRH3HRH1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL444425 | 0.73 | CYP1A2 (0.31) | SMN1; SMN2CYP2D6KCNH2 | |
| SCHEMBL3246677 | 0.72 | ALDH1A1 (0.33) | HRH1KDM4EALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL3154476 | 0.72 | HRH3 (0.57) | ESR1ESR2CXCR1TSHRHRH3 | |
| SCHEMBL3240661 | 0.71 | ALDH1A1 (0.35) | HRH3HRH1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1622611-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
| WO-2004096213-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | ESR1 694/4885ESR2 549/4885CXCR1 480/4885 |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | INSR, PTGER1, INSRR | ESR1 1953/4885ESR2 709/4885CXCR1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.